News and Views on Advances in Neovascular Retinal Disease Treatment: Weighing the Options
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Overview
Release Date: February 28, 2023
Expiration Date: February 28, 2024
Time to Complete Activity: 1.0 hour
Faculty
Arshad M. Khanani, MD, MA, FASRS
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Reno, NV
Jennifer I. Lim, MD, FARVO
Marion H. Schenk Esq. Chair and UIC Distinguished Professor of Ophthalmology
Director of Retina Service
Vice Chair for Diversity and Inclusion
University of Illinois at Chicago
Chicago, IL
Target Audience
This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians interested in the management of neovascular retinal diseases.
Provider Statement
This activity is provided by Paradigm Medical Communications, LLC. 
Supporter Acknowledgment
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Program Overview
The use of novel therapy for neovascular retinal diseases continues to be informed by mounting data and clinical experience clarifying benefit/risk profiles and appropriate patient selection, dosing intervals, and switching protocols. In this fast-paced news broadcast, experts will share real-life case studies and review the latest evidence to elucidate pressing clinical questions about novel therapy and guide modern treatment of neovascular retinal diseases in a wide variety of patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Examine the role of pathways beyond VEGF-A that are implicated in the development and progression of neovascular retinal diseases
- Compare the safety, efficacy, and durability of novel treatments with conventional treatments based on pivotal clinical trial data
- Select appropriate therapy for patients with nAMD and DME based on agent and patient characteristics, and with consideration of patient preferences
Accreditation
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Instructions for Participation
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Aerie Pharmaceuticals, Inc;
Aldebaran Therapeutics, Inc; Allergan, Inc; Apellis Pharmaceuticals, Inc; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals, Inc; Aviceda Therapeutics; Bausch & Lomb; Broadwing Bio; Chengdu Kanghong Pharmaceutical Group Co, LTD; Clearside BioMedical; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kartos Therapeutics, Inc; Kato Pharmaceuticals; Kodiak Sciences Inc; Kriya Therapeutics; Ocular Therapeutix, Inc; Oculis; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxurion NV; Nanoscope Therapeutics, Inc; Notal Vision, Inc; Novartis AG; Perfuse Therapeutics; PolyPhotonix Medical Ltd; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; RevOpsis Therapeutics LLC; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vial
Speaker’s Bureau: AbbVie Inc; Genentech, Inc.
Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Annexon Biosciences; Apellis Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; NGM Biopharmaceuticals Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; OcuTerra Therapeutics; Opthea; Oxurion NV; REGENXBIO Inc; UNITY Biotechnology
Stocks: Aviceda Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics LLC; Vial
Jennifer I. Lim, MD, FARVO
Advisor: Alimera Sciences; Regeneron Pharmaceuticals Inc
Consultant: Aura Biosciences, Inc.; Cognition Therapeutics; Eyenuk, Inc.; Genentech, Inc.; IVERIC bio, Inc; Luxa Biotechnology, LLC; NGM Biopharmaceuticals; Opthea; Quark Pharmaceuticals Inc. (exp. 2021);
Santen Pharmaceutical Co., Ltd. (exp. 2021); Novartis AG (exp. 2021); UNITY Biotechnology; Viridian Therapeutics Inc.
Research Funding: Adverum Biotechnologies, Inc; Aldeyra Therapeutics, Inc; Chengdu Kanghong Pharmaceutical Group Co, LTD (exp. 2021); Genentech, Inc.; Graybug Vision Inc (exp. 2021); Janssen Pharmaceuticals, Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Spring Vision LTD; Stealth BioTherapeutics Inc (exp. 2021)
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2023 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.